Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Amarin ( (AMRN)) has shared an ...

Amarin Corp.’s stock moved toward a new decade-high price in the extended session Friday after a Food and Drug Administration marketing approval that gave its drug Vascepa a wider use. U.S. traded ...

Amarin (AMRN) shares soared 12.5% in the last trading session to close at $18.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amarin (AMRN) one of those stocks right now? By taking a look ...

This site contains REAL public records data including criminal records, background reports, photos, court documents, address information, phone numbers, civil judgments, properties owned, social media ...

Amarin Corporation Plc (NASDAQ:AMRN) on Tuesday entered into an exclusive long-term license and supply agreement with Recordati S.p.A., Italy, to commercialize Vazkepa (icosapent ethyl) in 59 ...

With sales of its lone product in a precipitous decline in the United States, Amarin has turned to an experienced local partner to boost them in Europe. Amarin has forged a licensing deal with Italian ...

Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with ...

Amarin Corporation has appointed Peter Fishman as Chief Financial Officer, effective immediately. Fishman, who previously served as the Company’s Global Controller and principal financial and ...

On August 22, 2024, Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals, PLC (collectively Hikma), filed a petition for rehearing en banc, asking the US Court of Appeals for the Federal Circuit ...